{"nctId":"NCT01912716","briefTitle":"Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis","startDateStruct":{"date":"2013-07"},"conditions":["Post-ERCP Pancreatitis"],"count":1037,"armGroups":[{"label":"high-dose indomethacin","type":"EXPERIMENTAL","interventionNames":["Drug: high dose indomethacin"]},{"label":"standard dose indomethacin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: standard dose indomethacin"]}],"interventions":[{"name":"high dose indomethacin","otherNames":["Indocin"]},{"name":"standard dose indomethacin","otherNames":["Indocin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nIncluded patients are those undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and have:\n\none of the following:\n\n1. Clinical suspicion of sphincter of Oddi dysfunction (SOD; type I or II)\n2. History of post-ERCP pancreatitis (at least one episode)\n3. Pancreatic sphincterotomy\n4. Pre-cut (access) sphincterotomy\n5. greater than 8 cannulation attempts of any sphincter\n6. Pneumatic dilation of intact biliary sphincter\n7. Ampullectomy 8.) Assessment for post-sphincterotomy stenosis\n\nOR at least 2 of the following:\n\n1. Age less than 50 years old and female gender\n2. History of recurrent pancreatitis (at least 2 episodes)\n3. greater than or equal to to 3 pancreatic injections, with at least 1 injection to tail\n4. Pancreatic acinarization (excluding ventral pancreas of pancreas divisum)\n5. Pancreatic brush cytology -\n\nExclusion Criteria:\n\n1. Unwillingness or inability to consent for the study\n2. Age less than 18 years\n3. Intrauterine pregnancy\n4. Breastfeeding mother\n5. Standard contraindications to ERCP\n6. Allergy/hypersensitivity to aspirin or Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)\n7. Received NSAIDs in prior 7 days (aspirin 325mg or less ok)\n8. Renal failure (serum creatinine greater than 1.4)\n9. Active or recurrent (within 4 weeks) gastrointestinal hemorrhage\n10. Acute pancreatitis (lipase peak) within 72 hours\n11. Known chronic calcific pancreatitis\n12. Pancreatic head mass\n13. Procedure performed on major papilla/ventral pancreatic duct in patient with pancreas divisum (dorsal duct not attempted on injected)\n14. ERCP for biliary stent removal or exchange without anticipated pancreatogram\n15. Subject with prior biliary sphincterotomy now scheduled for repeat biliary therapy without anticipated pancreatogram\n16. Anticipated inability to follow protocol\n17. Known active cardiovascular or cerebrovascular disease -","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Developed Post-ERCP Pancreatitis","description":"Assessment of whether patients developed post-ERCP pancreatitis, defined as a new onset of pain (or worsening of existing pain) in the upper abdomen, an elevation in pancreatic enzymes of at least three times the upper limit of the normal range 24 hours after the procedure, and hospitalization for at least two nights.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Moderate or Severe Post-ERCP Pancreatitis","description":"Assessment of whether patients developed either moderate or severe post-ERCP pancreatitis, defined according to established consensus criteria (Cotton et al., Gastrointestinal Endoscopy 1991;37:383-93). Severity of post-ERCP pancreatitis is partly defined according to length of stay. Moderate pancreatitis is defined as a 4-10 day hospitalization. Severe post-ERCP pancreatitis is defined as a hospitalization of greater than 10 days post-ERCP, or development of a complication (eg. pseudocyst or necrosis), or need for intervention (drainage or surgery).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83,"n":515},"commonTop":[]}}}